Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

INTRODUCTION: Cutaneous adverse events (AEs) have been observed in clinical studies of daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis (RRMS). Here, we report cutaneous AEs observed in the randomized, double-blind, active-comparator DECIDE study (ClinicalTrials.gov iden...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Ther
Main Authors: Krueger, James G., Kircik, Leon, Hougeir, Firas, Friedman, Adam, You, Xiaojun, Lucas, Nisha, Greenberg, Steven J., Sweetser, Marianne, Castro-Borrero, Wanda, McCroskery, Peter, Elkins, Jacob
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4939160/
https://ncbi.nlm.nih.gov/pubmed/27251051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-016-0353-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados